Dextran-hemoglobin conjugates as blood substitutes
CA 2422908 A1 · Owner: Tsai, Sheung Pun · Inventors: Tsai, Sheung Pun; Wong, Jeffrey Tze-Fei
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An hemoglobin (Hb) - Dextran (Dx) conjugate having a molecular weight between 50 kD and 500 kD provides a blood substitute that results in acceptable erythrocyte sedimentation rate (ESR) and excretion rate (EXC) values. DxHb conjugates of the invention can be used for a variety of purposes as an alternative to blood.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 19, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 19, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 19, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.